{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:54:51Z","timestamp":1787939691074,"version":"build-2784847793"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gypenosides (Gyps), the major botanical component of <jats:italic>Gynostemma pentaphyllum<\/jats:italic>, was found to up-regulate the farnesoid X receptor (FXR) in a mouse model of non-alcoholic steatohepatitis (NASH). However, the exact role of FXR and underlying mechanisms in Gyps-mediated effects on NASH remain to be elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study investigated whether Gyps attenuates NASH through directly activating FXR in high-fat diet (HFD)-induced NASH, and delineated the molecular pathways involved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>A mouse model of HFD-induced NSAH was used to examine effects of Gyps on NASH with obeticholic acid (OCA) as a positive control, and the role of FXR in its mechanism of action was investigated in wild-type (WT) and FXR knockout (KO) mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>WT or FXR KO mice were randomly assigned into four groups: normal diet (ND) group as negative control, HFD group, HFD + Gyps group, or HFD + OCA group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with Gyps and OCA significantly improved liver histopathological abnormalities in HFD-induced NASH, reduced the non-alcoholic fatty liver disease (NAFLD) activity score (NAS), and lowered hepatic triglyceride (TG) content compared with the HFD group. In agreement with these liver tissue changes, biochemical tests of blood samples revealed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), and fasting insulin (FINS) levels were significantly lower in the HFD + Gyps vs. HFD group. Furthermore, Gyps and OCA treatment significantly up-regulated hepatic FXR, small heterodimer partner (SHP), carnitine palmitoyltransferase 1A (CPT1A), and lipoprotein lipase (LPL) expression, and significantly down-regulated sterol-regulatory element binding protein 1 (SREBP1), fatty acid synthetase (FASN), and stearoyl-CoA desaturase 1 (SCD1) protein levels compared with the HFD group in WT mice but not in FXR KO mice. Notably, Gyps- and OCA-mediated pharmacological effects were significantly abrogated by depletion of the FXR gene in FXR KO mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gyps ameliorated HFD-induced NASH through the direct activation of FXR and FXR-dependent signaling pathways.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2022.914079","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T06:44:40Z","timestamp":1661323480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation"],"prefix":"10.3389","volume":"9","author":[{"given":"Hongshan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/tp.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH.","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease.","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cld.2017.08.012","article-title":"Current treatment of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis.","volume":"22","author":"Hung","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.2174\/1568026619666191114104718","article-title":"Medicinal value and potential therapeutic mechanisms of Gynostemma pentaphyllum (Thunb.) makino and its derivatives: an overview.","volume":"19","author":"Li","year":"2019","journal-title":"Curr Top Med Chem."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8384631","article-title":"Gynostemma pentaphyllum Attenuates the progression of nonalcoholic fatty liver disease in mice: a biomedical investigation integrated with in silico assay.","volume":"2018","author":"Hong","year":"2018","journal-title":"Evid Based Complement Alternat Med."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1847629","article-title":"Bifidobacterium animalis: the missing link for the cancer-preventive effect of Gynostemma pentaphyllum.","volume":"13","author":"Liao","year":"2020","journal-title":"Gut Microbes."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26030570","article-title":"Protective effects of Gynostemma pentaphyllum (var. Ginpent) against lipopolysaccharide-induced inflammation and motor alteration in mice.","volume":"26","author":"Mastinu","year":"2021","journal-title":"Molecules."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/jsfa.8013","article-title":"Characteristics, composition, and antioxidant activities in vitro and in vivo of Gynostemma pentaphyllum (Thunb.) Makino seed oil.","volume":"97","author":"Wang","year":"2017","journal-title":"J Sci Food Agric."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1142\/s0192415x17500574","article-title":"Gypenosides ameliorate carbon tetrachloride-induced liver fibrosis by inhibiting the differentiation of hepatic progenitor cells into myofibroblasts.","volume":"45","author":"Chen","year":"2017","journal-title":"Am J Chin Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1080\/15384101.2020.1829800","article-title":"Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS\/TLR4 signaling pathway.","volume":"19","author":"Shen","year":"2020","journal-title":"Cell Cycle."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-020-00454-y","article-title":"Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis.","volume":"17","author":"Li","year":"2020","journal-title":"Nutr Metab (Lond)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1248\/bpb.b16-00942","article-title":"Therapeutic effect of gypenosides on nonalcoholic steatohepatitis via regulating hepatic lipogenesis and fatty acid oxidation.","volume":"40","author":"Li","year":"2017","journal-title":"Biol Pharm Bull."},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jep.2017.01.033","article-title":"Luhong formula inhibits myocardial fibrosis in a paracrine manner by activating the gp130\/JAK2\/STAT3 pathway in cardiomyocytes.","volume":"202","author":"Qu","year":"2017","journal-title":"J Ethnopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease.","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","article-title":"Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.","volume":"19","author":"Koo","year":"2013","journal-title":"Clin Mol Hepatol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease.","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101115","article-title":"Hepatic lipid droplets: a balancing act between energy storage and metabolic dysfunction in NAFLD.","volume":"50","author":"Mashek","year":"2020","journal-title":"Mol Metab."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109721","article-title":"Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model.","volume":"123","author":"Sun","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial.","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109609","article-title":"Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.","volume":"121","author":"Xi","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.phymed.2016.12.006","article-title":"Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.","volume":"25","author":"Duan","year":"2017","journal-title":"Phytomedicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/jci21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.","volume":"113","author":"Watanabe","year":"2004","journal-title":"J Clin Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1096\/fj.201802619RR","article-title":"Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway.","volume":"33","author":"Liu","year":"2019","journal-title":"Faseb J."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0464-z","article-title":"Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1\/AMPK\u03b1\/SREBP1 signaling pathway.","volume":"16","author":"Wang","year":"2017","journal-title":"Lipids Health Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives.","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753681","article-title":"LPS stimulation induces small heterodimer partner expression through the AMPK-NRF2 pathway in large yellow croaker (Larimichthys crocea).","volume":"12","author":"Du","year":"2021","journal-title":"Front Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1053\/j.gastro.2018.11.061","article-title":"Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption.","volume":"156","author":"Kim","year":"2019","journal-title":"Gastroenterology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40495-017-0085-2","article-title":"Role of FXR in liver inflammation during nonalcoholic steatohepatitis.","volume":"3","author":"Armstrong","year":"2017","journal-title":"Curr Pharmacol Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2147\/dddt.s170518","article-title":"Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.","volume":"12","author":"Hu","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/jci134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest."},{"key":"B37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/meg.0000000000001483","article-title":"Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease.","volume":"32","author":"Ye","year":"2020","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.26442\/terarkh201890863-68","article-title":"The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease.","volume":"90","author":"Shipovskaya","year":"2018","journal-title":"Ter Arkh."},{"key":"B39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease.","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bbadis.2010.01.002","article-title":"The bile acid sensor FXR regulates insulin transcription and secretion.","volume":"1802","author":"Renga","year":"2010","journal-title":"Biochim Biophys Acta."},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mce.2015.07.012","article-title":"Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance.","volume":"414","author":"Shihabudeen","year":"2015","journal-title":"Mol Cell Endocrinol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance.","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/joe-13-0109","article-title":"FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS.","volume":"218","author":"Maneschi","year":"2013","journal-title":"J Endocrinol."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.914079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T06:44:42Z","timestamp":1661323482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.914079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":43,"alternative-id":["10.3389\/fnut.2022.914079"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2022.914079","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"914079"}}